Pediatrix Medical Group (NYSE:MD) Stock Price Expected to Rise, UBS Group Analyst Says

Pediatrix Medical Group (NYSE:MD) had its price target lifted by UBS Group from $10.50 to $16.50 in a report published on Tuesday,Benzinga reports. UBS Group currently has a neutral rating on the stock.

A number of other equities analysts also recently issued reports on the company. StockNews.com upgraded Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research note on Wednesday, August 7th. Jefferies Financial Group boosted their target price on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday. Deutsche Bank Aktiengesellschaft upped their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research report on Monday. Mizuho increased their price objective on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Monday. Finally, Truist Financial increased their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a research note on Monday. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Pediatrix Medical Group presently has an average rating of “Hold” and a consensus price target of $16.10.

Pediatrix Medical Group Price Performance

NYSE MD traded down $0.26 during trading on Tuesday, hitting $15.78. 126,575 shares of the company’s stock were exchanged, compared to its average volume of 869,837. The company has a market cap of $1.36 billion, a PE ratio of -5.24, a P/E/G ratio of 2.35 and a beta of 1.55. The company has a current ratio of 1.42, a quick ratio of 1.38 and a debt-to-equity ratio of 0.83. The stock’s 50 day moving average price is $11.99 and its two-hundred day moving average price is $9.59. Pediatrix Medical Group has a fifty-two week low of $6.62 and a fifty-two week high of $16.41.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The firm had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.29 EPS. Research analysts expect that Pediatrix Medical Group will post 1.19 EPS for the current year.

Insider Activity at Pediatrix Medical Group

In other news, CFO C Marc Richards sold 17,438 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $10.08, for a total transaction of $175,775.04. Following the transaction, the chief financial officer now directly owns 175,347 shares of the company’s stock, valued at approximately $1,767,497.76. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CFO C Marc Richards sold 17,438 shares of Pediatrix Medical Group stock in a transaction on Monday, August 12th. The shares were sold at an average price of $10.08, for a total transaction of $175,775.04. Following the completion of the sale, the chief financial officer now directly owns 175,347 shares in the company, valued at approximately $1,767,497.76. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO James D. Swift sold 11,100 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $10.79, for a total transaction of $119,769.00. Following the transaction, the chief executive officer now directly owns 170,001 shares of the company’s stock, valued at approximately $1,834,310.79. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,538 shares of company stock valued at $373,664. Insiders own 1.20% of the company’s stock.

Institutional Trading of Pediatrix Medical Group

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Pediatrix Medical Group by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock worth $105,892,000 after acquiring an additional 164,333 shares during the last quarter. Rubric Capital Management LP lifted its holdings in Pediatrix Medical Group by 797.0% during the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after buying an additional 7,241,400 shares in the last quarter. Boston Partners raised its holdings in shares of Pediatrix Medical Group by 34.0% in the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after purchasing an additional 453,254 shares in the last quarter. Dana Investment Advisors Inc. raised its stake in Pediatrix Medical Group by 80.3% during the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after acquiring an additional 455,785 shares in the last quarter. Finally, Brandes Investment Partners LP raised its stake in Pediatrix Medical Group by 12.8% during the 2nd quarter. Brandes Investment Partners LP now owns 735,068 shares of the company’s stock worth $5,438,000 after acquiring an additional 83,588 shares in the last quarter. Hedge funds and other institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.